John II

Mr Pinion II is a resident of the US. He has over 30 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe, and the Americas. His expertise and leadership spans engineering, quality, manufacturing, and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. He is also Chair of Risk committee.

Company and Role

Company
Title
Tenure
Since
ARX
Aroa Biosurgery Limited
  • Non-Executive Director
9yrsFeb 2015

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ARX
Aroa Biosurgery Limited
31/03/23472,500N/A1,051,620N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ARX
Aroa Biosurgery Limited
31/03/23
Issued
172,620$1.050$181,251Issue of options